Free Trial
NASDAQ:NEPH

Nephros (NEPH) Stock Price, News & Analysis

Nephros logo
$2.92 +0.29 (+11.03%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.82 -0.11 (-3.60%)
As of 05/23/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nephros Stock (NASDAQ:NEPH)

Key Stats

Today's Range
$2.62
$2.96
50-Day Range
$1.49
$2.92
52-Week Range
$1.36
$2.96
Volume
75,079 shs
Average Volume
12,307 shs
Market Capitalization
$30.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Nephros Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

NEPH MarketRank™: 

Nephros scored higher than 38% of companies evaluated by MarketBeat, and ranked 644th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nephros has received no research coverage in the past 90 days.

  • Read more about Nephros' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nephros is -32.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nephros is -32.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nephros has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Nephros' valuation and earnings.
  • Percentage of Shares Shorted

    0.09% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nephros has recently decreased by 28.95%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nephros does not currently pay a dividend.

  • Dividend Growth

    Nephros does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.09% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nephros has recently decreased by 28.95%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    1 people have added Nephros to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nephros insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.70% of the stock of Nephros is held by insiders.

  • Percentage Held by Institutions

    41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nephros' insider trading history.
Receive NEPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

NEPH Stock News Headlines

Memorial Day Sale! 82% Off Disruptors and Dominators!
Robots aren't coming to America in 2025. They are already here. In fact, I believe these robots could impact 65 million Americans lives — by August of this year.
Nephros Launches New S100 In-Line Microfilter
Nephros Full Year 2024 Earnings: Beats Expectations
See More Headlines

NEPH Stock Analysis - Frequently Asked Questions

Nephros' stock was trading at $1.47 on January 1st, 2025. Since then, NEPH stock has increased by 98.6% and is now trading at $2.92.
View the best growth stocks for 2025 here
.

Nephros, Inc. (NASDAQ:NEPH) released its earnings results on Thursday, May, 15th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.06. The company had revenue of $4.88 million for the quarter, compared to analyst estimates of $3.67 million. Nephros had a negative net margin of 6.86% and a negative trailing twelve-month return on equity of 11.39%.

Nephros' top institutional shareholders include Bard Associates Inc. (1.35%). Insiders that own company stock include Arthur H Amron and Robert R Jr Banks.
View institutional ownership trends
.

Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
5/15/2025
Today
5/24/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NEPH
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+71.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,580,000.00
Pretax Margin
-6.86%

Debt

Sales & Book Value

Annual Sales
$15.52 million
Price / Cash Flow
N/A
Book Value
$0.80 per share
Price / Book
3.65

Miscellaneous

Free Float
10,112,000
Market Cap
$30.95 million
Optionable
Not Optionable
Beta
0.81
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:NEPH) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners